Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
—Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 mutation have outcomes that are inferior to those in patients with normal ...
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback